Astrazeneca Ab

Astex Therapeutics Limited

Eolas Therapeutics, Inc.

Jörg Holenz

Roland W Bürli

Karin Kolmodin

Laszlo Rakos

Miles Stuart Congreve

Christopher William Murray

Gianni Chessari

Theodore M Kamenecka

Stefan Von Berg

Yuanjun He

Steven Sigmund Wesolowski

Didier Rotticci

Sahil Patel

Mark E Duggan

Stefan Berg

Gunnar Nordvall

Annika Kers

Britt-Marie Swahn

Philip Vellacott Thorne

Daniel Sohn

Phil Edwards

Alexander Minidis

James Arnold

Peter Söderman

Jenny Viklund

Ylva Gravenfors

Sofia Karlström

Liselotte Öhberg

Johan Bylund

Rotticci Didier

Maria E Ek

Karl S A Vallin

Patrik Johansson

Michael John McKenzie

Johan Lindström

Mark Sylvester

Karl SA Vallin

The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

Halo-substituted piperidines as orexin receptor modulators

The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A&#x3b2;-related pathologies such as Down's syndrome, &#x3b2;-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ('mild cognitive impairment'), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

Compounds and their use as BACE inhibitors

The invention provides compounds of formula (I) wherein R, R, L, L, G, G, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1. 

Bis-(sulfonylamino) derivatives for use in therapy

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A&#x3b2;-related pathologies such as Downs syndrome, &#x3b2;-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ('mild cognitive impairment'), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. 

Substituted isoindoles for the treatment and/or prevention of A&#x3b2;- related pathologies

This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Compounds

This invention relates to substituted pyrrolo[3,4-b]pyridinamines having the structural formula IA below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions

Growing community of inventors

Södertälje, Sweden

Jörg Holenz